Tag: labelling
-
Heritage Cannabis (CANN.C) launches new consumer product as global cannabis stocks rally 61% in Q4, 2020
CANN focuses on extraction and the creation of derivative products for recreational and medical consumers.
-
Heritage Cannabis (CANN.C) granted oil sales licence – CannaCure’s Fort Erie facility in focus
CannaCure’s goal is “to transform the global marijuana landscape through innovative growth strategies and strategic partnerships with manufacturers of cannabis products.”
-
Heritage Cannabis (CANN.C) is so close profitability, it’s breaking social distancing rules
Sharples believes that Purefarma, Pura Vida, new contract manufacturing agreements, expansion of Canadian territories, the edibles product launch and the acquisition of Opticann expanding CANN’s U.S. presence will accelerate revenue going forward.
-
Heritage Cannabis (CANN.C) to develop vape oil with Sugarbud’s biomass
Heritage is positioning itself to radically expand its sales territory.
-
Heritage Cannabis (CANN.C) acquires Opticann – to create an international medical footprint
Sharples’ plan is to leverage Opticann’s international relationships to build “an international medical product sales footprint”.
-
Heritage Cannabis (CANN.C) releases Q2, 2020 financials
Gross revenue was $1.4-million in the second quarter of 2020, compared with nil in the three-month period ended April 30, 2019.
-
Heritage Cannabis (CANN.C) launches branded products
Growing cannabis revenues, shrinking losses, a healthy balance sheet – and now a pathway to selling branded extraction products into the Canadian market.
-
Do not adjust your TV sets – Heritage Cannabis (CANN.C) is a real business
New licenses, deals, products – that’s all good – but it’s not the nitty gritty stuff investors are looking for now. By “nitty-gritty” we mean – numbers. Four weeks ago, Heritage released its Q1, 2020 financials.
-
The Good, the Bad & the Ugly; Trulieve Cannabis (TRUL.C), KushCo Holdings (KSHB.OTC) and Hexo (HEXO.NYSE) release financials
“Borrowing money and expanding hard in competition with MedMen (MMEN.C) is a two-edged sword,” explained Equity Guru’s Chris Parry, “In a strong market, you’re building far more value than you’re borrowing but, in a down market, you’re under extra pressure to keep things together when debts come due.”